Delaware
|
|
001-34079
|
|
11-3516358
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.0001 per share
|
OCUP
|
The Nasdaq Stock Market LLC
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits
|
Exhibit
Number
|
Exhibit Description
|
|
Corporate Presentation, dated August 1, 2023
|
||
104
|
Cover Page Interactive Data File (embedded within Inline XBRL document).
|
|
OCUPHIRE PHARMA, INC.
|
|
|
|
|
|
|
|
Date: August 1, 2023
|
By:
|
/s/ Richard J. Rodgers
|
|
|
Richard J. Rodgers
|
|
|
Interim President and Chief Executive Officer
|